GleamWall
中文EN

CLCS Cell Source, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1569340 · Fiscal year ends 12/31

Financial factors as of 2025-03-31 (2025Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY3.8%
TTM EPS YoY12.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-2,516.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets6,985.4%
Debt / equity—
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.66x
Accruals ratio-857.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-302024Q12024-03-312023Q4*2023-12-312023Q32023-09-302023Q22023-06-30
Income statement
Revenue————————
SG&A expense$483,404$315,811$470,768$373,668$781,916$506,950$480,875$539,877
Operating income-$998,587-$676,811-$831,625-$1.19M-$1.14M-$1.01M-$995,380-$905,465
Net income-$1.48M-$331,307-$1.42M-$1.49M-$1.28M-$1.05M-$1.34M-$1.24M
EPS (basic)-0.04—-0.04-0.04-0.04—-0.04-0.04
EPS (diluted)-0.04—-0.04-0.04-0.04—-0.04-0.04
Weighted avg. shares (diluted)45.04M—42.43M41.02M40.51M—38.19M37.21M
Balance sheet
Cash & equivalents$1,240$74,631$22,992$90,549$23$22,203$2,582$21,993
Total assets$292,446$286,500$264,660$429,767$82,589$195,171$248,357$362,329
Total liabilities$20.43M$18.82M$19.21M$17.75M$16.84M$15.81M$16.28M$15.31M
Shareholders' equity-$20.14M-$18.54M-$18.94M-$17.32M-$16.75M-$15.61M-$16.03M-$14.95M
Shares outstanding45.04M45.04M43.25M41.94M41.02M39.83M38.50M38.16M
Cash flow statement
Operating cash flow-$600,391-$748,326-$639,010-$1.12M-$173,852-$722,290-$279,969-$1.04M
Financing cash flow$527,000$799,965$571,453$1.21M$151,672$741,911$260,558$925,000
Stock-based compensation$104,475-$20,873$5,070$15,332$288,895$58,056$25,962$50,111

Free plan shows the latest 8 periods; Pro shows all 50 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.